Skip to main content
. Author manuscript; available in PMC: 2008 Dec 19.
Published in final edited form as: Neuroscience. 2007 Oct 5;150(4):807–817. doi: 10.1016/j.neuroscience.2007.09.060

Figure 3. Pharmacological characterization of antihyperalgesia induced by deltorphin II.

Figure 3

A, The antihyperalgesic effect of deltorphin II in CFA-injected C57BL/6 mice was DOR-mediated since it was completely blocked by naltrindole (n = 9) but not significantly affected by CTOP (n = 6). Naltrindole was administered subcutaneously at a dose of 10 mg/kg, 15 min prior to deltorphin II (2.5 μg) injection. CTOP (10 ng) was co-injected intrathecally with deltorphin II (2.5 μg). This dose of CTOP (10 ng; n = 6) was sufficient to fully reverse DAMGO (5 ng)-induced antihyperalgesia (n = 6), demonstrating the appropriateness of the CTOP dose. *, p < 0.05, one-way ANOVA followed by Bonferroni’s multiple comparison test. B, As for deltorphin II, antihyperalgesic effect of intrathecally administered SNC80 (45 μg), a non-peptide DOR-selective agonist, was significantly weaker in MOR-KO mice (n = 10) than in littermate controls (n = 9). Vehicle control has no effect by itself (n = 8). *, p < 0.05, one-way ANOVA followed by Bonferroni’s multiple comparison test. A and B, the effect of each treatment is expressed as %MPAHE, calculated 15 minutes post-injection.